Business Information
The group's principal activities are to develop and market proprietary pharmaceutical products with new formulations, enhanced delivery systems and expanded indications. Its focus is development and commercialization of next generation proton pump inhibitor or ppi products which are frequently prescribed drugs for the treatment of many upper gastrointestinal, or gi, diseases and disorders. The group's product candidates are rapinex powder-for-suspension, rapinex capsule and rapinex chewable tablet, are proprietary immediate-release formulations of omeprazole which are intended to treat or prevent a variety of upper gi diseases and disorders including heartburn, gastroesophageal reflux disease, or gerd, erosive esophagitis, or ee, upper gi bleeding and peptic ulcer diseases. The other two product candidates that provide an alternative formulations of immediate-release omeprazole are rapinex capsule and rapinex chewable tablet.
|
|
Name |
Title
|
Email
|
| David Hale | Chmn. | N/A | | Debra Crawford | Sr. VP, CFO, Treasurer, Sec. | N/A | | Blake Boland | VP - Sales | N/A | | David Ballard | VP - Clinical Research, Medical Affairs | N/A | | E. Ballard | VP - Clinical Research, Medical Affairs | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 49,242 | (56,466) | | 2005 | 26,524 | (64,986) | | 2004 | 1,348 | (81,495)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
